RECOVER-VITAL clinical trial finds no benefit of extended duration of PAXLOVID for Long COVID
Peer-Reviewed Publication
Updates every hour. Last Updated: 27-Oct-2026 03:16 ET (27-Oct-2026 07:16 GMT/UTC)
Results from a clinical trial funded by the National Institutes of Health (NIH) and published today in the journal Lancet Infectious Diseases show that the antiviral drug, PAXLOVID, commonly prescribed to treat acute COVID-19, does not have an impact on Long COVID symptoms when compared to placebo.
Regular aerobic exercise – the kind that gets your heart pumping – can improve important thinking skills called executive functions, and the benefits appear especially strong for women after menopause, according to Rutgers researchers.
Dr. Emily Flanagan, Assistant Professor and Director of the Developmental Physiology Laboratory at LSU’s Pennington Biomedical Research Center, has been awarded a prestigious National Institutes of Health R01 grant totaling up to $3.55 million to investigate how energy intake and expenditure influence infant growth during the first year of life.
The five-year grant from the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases will support Flanagan’s project, “Characterization of Infant Energy Balance to Optimize Early Life Growth.” The study will examine the fundamental drivers of infant growth and could help improve how energy needs are estimated during a critical period of development.